Skip to main content
OpenTrials
Completed

NCT Number: NCT01428115

Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab

It has been shown that emotional health issues, such as state anxiety, are more prevalent in patients suffering from inflammatory bowel disease (IBD) compared to physically healthy subjects.

Such findings have to be taken into consideration when making an educated guess that psychological factors such as depression and anxiety in particular interact with the course of Crohns disease. Therefore the treatment of the underlying disease may have a significant influence on the level of psychological disorders.

Several studies have shown that treatment with tumor necrosis factor alpha (TNF-α) antibodies ameliorates the emotional/psychological status of patients, however the impact of adalimumab therapy on anxiety correlated with the status of inflammatory bowel disease (IBD) remains unclear.

The primary objective of this study was to describe and evaluate changes in levels of anxiety assessed by validated patient questionnaires after 6 months of treatment with adalimumab.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Severe Crohn's Disease Anxiety Anxiety Disorders Crohn Disease Digestive System Diseases Gastroenteritis Gastrointestinal Diseases Inflammatory Bowel Diseases Intestinal Diseases Mental Disorders

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Site Reference ID/Investigator# 64830, Graz, Austria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients for whom Adalimumab (Humira) therapy is indicated and has been prescribed according to the product label and who meet the following criteria:
  • Male and female patients aged 18 to 65 years suffering from severe active Crohns Disease, attending a routine medical visit.
  • Able to complete questionnaires.
  • Patients with status active severe Crohns disease which required immunosuppressive treatment
  • Patients must fulfil international and national guidelines for the use of a biologic therapies in Crohns Disease (Chest X-ray and interferon gamma release assay (IGRA) or PPD (purified protein derivative)-skin test negative for tuberculosis).
  • Patients have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.
  • Patients who have been prescribed in line with the European Summary of Product Characteristics (SMPC)

Exclusion criteria

  • The following patients will not be included in this observational study:
  • Previous therapy with TNF-α blocker within the last 8 weeks
  • Active Central Nervous System opportunistic infections or Central Nervous System malignancies.
  • History of Cerebrovascular Accident
  • Abuse of illicit substances (such as psychoactive drugs) within the previous 3 months
  • Change of medication-based treatment of generalized anxiety and panic disorder, psychiatric disorder
  • No informed consent
  • Contraindication to adalimumab (Humira) therapy according to the SMPC
  • Current or planned pregnancy
  • Lactation according to SMPC
  • Planned change of site within the next 24 weeks.

Treatment and study plan

Primary outcomes

  1. Change in State Trait Anxiety Index (STAI) State Scores From Baseline to After 6 Months of Treatment With Adalimumab

    Time frame: Baseline and Visit 3 [Month 6]

    The STAI questionnaire consists of 40 questions with 20 items allocated to each of the State Anxiety and Trait Anxiety subscales. The scores for each subtest range from 20 to 80, with higher scores indicating higher levels of anxiety.

  2. Change in State Trait Anxiety Index (STAI) Trait Scores From Baseline to After 6 Months of Treatment With Adalimumab

    Time frame: Baseline and Visit 3 [Month 6]

    The STAI questionnaire consists of 40 questions with 20 items allocated to each of the State Anxiety and Trait Anxiety subscales. The scores for each subtest range from 20 to 80, with higher scores indicating higher levels of anxiety.

  3. Change in Hospital Anxiety and Depression Score (HADS) - Anxiety, From Baseline to After 6 Months of Treatment With Adalimumab

    Time frame: Baseline and Visit 3 [Month 6]

    HADS is used to detect emotional disturbances (such as anxiety and depression) in non-psychiatric patients treated at hospital clinics. It consists of 14 items with 7 items relating to anxiety and to depression respectively. Each item is scored from 0 to 3 therefore scores for each subscale range from 0 to 21 with higher scores indicating higher levels of anxiety and depression. The scores were categorized as follows: 0 to 7 was normal, 8 to 10 was suggestive, and 11 to 21 was case.

  4. Change in Hospital Anxiety and Depression Score (HADS) - Depression, From Baseline to After 6 Months of Treatment With Adalimumab

    Time frame: Baseline and Visit 3 [Month 6]

    HADS is used to detect emotional disturbances (such as anxiety and depression) in non-psychiatric patients treated at hospital clinics. It consists of 14 items with 7 items relating to anxiety and to depression respectively. Each item is scored from 0 to 3 therefore scores for each subscale range from 0 to 21 with higher scores indicating higher levels of anxiety and depression. The scores were categorized as follows: 0 to 7 was normal, 8 to 10 was suggestive, and 11 to 21 was case.

Secondary outcomes

  1. Short Inflammatory Bowel Disease Questionnaire (sIBDQ) Scores by Visit

    Time frame: Visit 1 [Baseline], Visit 2 [Month 3], and Visit 3 [Month 6]

    The sIBDQ is a disease-specific health-related quality of life (HRQoL) questionnaire, able to detect and define meaningful clinical changes in inflammatory bowel disease (IBD) patients by measuring physical, social and emotional status. The sIBDQ consists of 10 questions, each question is scored on a scale from 1 (poor QoL) to 7 (good QoL). The scores are summed up and divided by 10 for a mean score ranging from 1 (poor QoL) to 7 (good QoL). A higher score indicates a better HRQoL.

  2. Harvey-Bradshaw Index (HBI) Scores by Visit

    Time frame: Visit 1 [Baseline], Visit 2 [Month 3], and Visit 3 [Month 6]

    Harvey-Bradshaw Index (HBI) is for use in the assessment and quantification of symptoms and the present level of disease activity of patients with Crohn's disease. It is a validated clinical index for Crohn's disease, including the 5 categories of: general well-being, abdominal pain, number of liquid stools, abdominal mass and complications. The score ranges from 0 to 25 with higher scores indicating higher disease activity. The scores were classified as follows: less than 5 is remission, 5 to 7 is mild, 8 to 16 is moderate, and greater than 16 is severe.

  3. State Trait Anxiety Index (STAI) State Scores by Visit

    Time frame: Visit 1 [Baseline], Visit 2 [Month 3], and Visit 3 [Month 6]

    The STAI questionnaire consists of 40 questions with 20 items allocated to each of the State Anxiety and Trait Anxiety subscales. The scores for each subtest range from 20 to 80, with higher scores indicating higher levels of anxiety.

  4. State Trait Anxiety Index (STAI) Trait Scores by Visit

    Time frame: Visit 1 [Baseline], Visit 2 [Month 3], and Visit 3 [Month 6]

    The STAI questionnaire consists of 40 questions with 20 items allocated to each of the State Anxiety and Trait Anxiety subscales. The scores for each subtest range from 20 to 80, with higher scores indicating higher levels of anxiety.

  5. Hospital Anxiety and Depression Score (HADS) - Anxiety Scores by Visit

    Time frame: Visit 1 [Baseline], Visit 2 [Month 3], and Visit 3 [Month 6]

    HADS is used to detect emotional disturbances (such as anxiety and depression) in non-psychiatric patients treated at hospital clinics. It consists of 14 items with 7 items relating to anxiety and to depression respectively. Each item is scored from 0 to 3 therefore scores for each subscale range from 0 to 21 with higher scores indicating higher levels of anxiety and depression. The scores were categorized as follows: 0 to 7 was normal, 8 to 10 was suggestive, and 11 to 21 was case.

  6. Hospital Anxiety and Depression Score (HADS) - Depression Scores by Visit

    Time frame: Visit 1 [Baseline], Visit 2 [Month 3], and Visit 3 [Month 6]

    HADS is used to detect emotional disturbances (such as anxiety and depression) in non-psychiatric patients treated at hospital clinics. It consists of 14 items with 7 items relating to anxiety and to depression respectively. Each item is scored from 0 to 3 therefore scores for each subscale range from 0 to 21 with higher scores indicating higher levels of anxiety and depression. The scores were categorized as follows: 0 to 7 was normal, 8 to 10 was suggestive, and 11 to 21 was case.

Sponsors and collaborators

Lead sponsor

AbbVie (prior sponsor, Abbott)

Industry

Collaborators

  • Raffeiner GmbH

Registry information

Acronym: RELAX

Important dates

Study start
2011
Primary completion
2013
Study completion
2013
First posted
Sep 2, 2011
Registry last updated
Nov 3, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.